GLP-1 Medication Costs Without Insurance: A Complete Breakdown

Disclaimer: Insurance and cost information changes frequently. Always verify current coverage details with your insurer and prescriber.

The Real List Prices for Each Medication

The list prices for GLP-1 medications — what you would pay with no insurance and no discount programs — are among the highest of any medication class in the United States. Here are the approximate 2024–2025 monthly list prices for each major drug:

• Ozempic (semaglutide, diabetes)Approximately $935–$1,000 per month (0.5 mg, 1 mg, or 2 mg auto-injector pen)
• Wegovy (semaglutide, obesity)Approximately $1,349–$1,400 per month (maintenance dose 2.4 mg)
• Mounjaro (tirzepatide, diabetes)Approximately $1,023–$1,100 per month (across dose tiers)
• Zepbound (tirzepatide, obesity)Approximately $1,060–$1,100 per month (across dose tiers)
• Rybelsus (oral semaglutide, diabetes)Approximately $900–$950 per month

At these prices, a year of treatment at full list price could cost $11,000 to $17,000. Even with insurance, patients often face high copays or deductibles before coverage kicks in. The good news is that very few commercially insured patients — and almost no uninsured patients who actively pursue assistance programs — actually pay full list price.

Why GLP-1 Medications Cost So Much

The high prices of GLP-1 medications reflect several compounding factors. First, both Novo Nordisk and Eli Lilly invested decades and billions of dollars in developing these drugs. Novo Nordisk's research into GLP-1 compounds dates to the 1980s, and the path from basic science to FDA-approved medication involves clinical trials that can cost $1–$2 billion per drug.

Second, patent protection gives manufacturers a period of market exclusivity — typically around 20 years from filing, though effective exclusivity after approval is shorter. During this period, no generic competition exists to drive down prices. The earliest that generic semaglutide could enter the market is the late 2020s, and generic tirzepatide would follow several years after that.

Third, U.S. drug pricing norms differ fundamentally from the rest of the world. In Germany, France, and the United Kingdom, health technology assessment bodies negotiate drug prices based on clinical value. Ozempic costs approximately $59 per month in Germany and around $190 per month in Canada. The U.S. system, which has historically prohibited Medicare from negotiating prices and left commercial pricing largely unregulated, has produced list prices that are many multiples of what other countries pay.

Finally, demand has dramatically exceeded supply, giving manufacturers less incentive to compete on price. With millions of new patients seeking these drugs, neither company has needed to reduce prices to attract customers.

Manufacturer Patient Assistance Programs

Both Novo Nordisk and Eli Lilly offer cost-reduction programs that can dramatically lower — or entirely eliminate — your out-of-pocket costs. The structure differs based on whether you have commercial insurance, are uninsured, or are on a government plan like Medicare or Medicaid.

For commercially insured patients, manufacturer savings cards are the primary tool. The Ozempic Savings Offer and Wegovy Savings Offer from Novo Nordisk can reduce copays to as low as $25 per month for eligible patients. Eli Lilly's savings cards for Mounjaro and Zepbound function similarly, with copay caps around $25–$150 depending on your insurance situation. These cards are processed at the pharmacy like a secondary insurance policy.

For uninsured or underinsured patients, both manufacturers offer income-based Patient Assistance Programs (PAPs). Novo Nordisk's NovoCare Patient Assistance Program provides free Ozempic to patients without insurance coverage who meet income guidelines (generally up to 400% of the federal poverty level, approximately $60,000 for a single person in 2024). Eli Lilly's PAP operates on similar terms. Your prescribing physician must typically initiate the application on your behalf, and processing takes two to six weeks.

Note that Medicare and Medicaid enrollees generally cannot use manufacturer savings cards due to federal anti-kickback regulations, but may qualify for income-based PAPs. If you are on Medicare, see our separate guide on Medicare GLP-1 coverage and assistance options.

GoodRx and Pharmacy Discount Programs

GoodRx and similar discount programs (RxSaver, Blink Health, Cost Plus Drugs) work by negotiating bulk pricing with pharmacies and passing a portion of the savings to consumers. For most generic medications, these programs can save 80–90% off list price. For brand-name GLP-1s with no generics, the savings are more modest but can still be meaningful.

Using GoodRx for Ozempic, for example, typically yields prices in the $850–$950 range — slightly below the full list price but not dramatically so. For comparison, manufacturer savings cards for eligible commercially insured patients bring the cost down to $25/month, making GoodRx less compelling for those with commercial insurance.

Mark Cuban's Cost Plus Drugs (costplusdrugs.com) has been disrupting generic drug pricing by selling at a transparent markup over manufacturing cost. As of early 2025, Cost Plus does not carry brand-name semaglutide or tirzepatide — their model applies primarily to generic drugs. However, if and when generics become available, Cost Plus is likely to offer them at prices far below current list.

One important note: you generally cannot combine a manufacturer savings card with a GoodRx or other third-party discount card at the same time. Always compare both options for your specific situation to find the lower net price.

Compounding Pharmacies: The Cheapest Option?

During the 2022–2024 shortage of branded semaglutide and tirzepatide, compounding pharmacies stepped in to fill the gap. They could legally compound copies of drugs on the FDA's shortage list, and prices were dramatically lower — often $150–$350 per month compared to $900+ for the branded product.

However, the FDA removed semaglutide from its drug shortage list in early 2025, and tirzepatide shortages have also resolved. This changed the legal landscape significantly. Compounding of a drug that is not on the shortage list is only permitted under narrow circumstances — when a patient has a documented clinical need for a different formulation than what is commercially available (for example, a patient who cannot tolerate any of the standard excipients).

The FDA has issued warning letters to compounding pharmacies continuing to produce semaglutide after shortage removal, and enforcement actions are escalating. For patients, continuing to use compounded semaglutide carries both regulatory risk and genuine safety concerns — compounding pharmacies are not subject to the same quality control standards as commercial pharmaceutical manufacturers, and issues with dosing accuracy, sterility, and contamination have been documented.

For most patients, the cost advantage of compounded products is no longer worth the trade-off in legal clarity and product safety. The legitimate alternatives described in this article — manufacturer programs, telehealth cash-pay options, and aggressive use of assistance programs — now offer a better risk-adjusted path to affordability.

Telehealth and Cash-Pay Clinics

A growing ecosystem of telehealth and direct-pay obesity medicine practices has emerged to serve patients who lack insurance coverage or who find the traditional healthcare system difficult to navigate. Companies like Ro Body, Found, Calibrate, and Sequence offer online consultations and prescription management for GLP-1 medications — often bundled with lifestyle coaching and monitoring services.

These platforms do not typically reduce the cost of the branded medication itself — they still need to send a prescription to a pharmacy where you will pay the same list price, offset by any applicable savings cards. What they do offer is more convenient access, particularly for patients in areas without easy access to an endocrinologist or obesity medicine specialist, and sometimes assistance with prior authorization and appeals.

Eli Lilly has also launched LillyDirect, a direct-to-patient pharmacy service that allows patients to obtain Zepbound directly from Lilly, bypassing traditional pharmacy channels. As of 2025, Lilly was offering Zepbound through this channel at reduced self-pay prices — in the $350–$550 per month range for certain dose vials — specifically targeting uninsured and underinsured patients. This is one of the most compelling cash-pay options currently available and is worth checking directly at LillyDirect.com for current pricing and availability.

Novo Nordisk has been evaluating similar direct-to-patient models. The competitive pressure from Lilly's approach and from ongoing political scrutiny of drug prices may drive further price reduction initiatives from both companies in 2025 and beyond. Monitoring both manufacturers' patient access programs regularly is worthwhile.